Ozempic (R) was approved by Health Canada in 2018. Ozempic (R) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control.

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures ...

Zydus Lifesciences will roll out generic semaglutide injections in India post-patent expiry, using a reusable single-pen ...

PHOENIX, AZ - February 27, 2026 - PRESSADVANTAGE - Phoenix NP, a women-focused telehealth medical practice based in ...

With rising demand, healthcare authorities have issued guidance addressing compounded formulations. Patients frequently ask is compounded semaglutide safe, leading providers to clarify that safety ...

DCGI had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of Type 2 ...

Feb 25 - Zydus Lifesciences will launch generic versions of semaglutide injections for ‌obesity and diabetes in India after ‌patent expiry of the Ozempic active ingredient in ​late March, it said on ...

Zydus to launch Semaglutide Injection in India, featuring a unique reusable pen for improved diabetes and obesity management.

A new animal study raises important questions about a little-known ingredient used in oral weight-loss medications. A pill can feel simpler than a shot, but it also changes what else your body is ...

Cost-effectiveness is highly price-sensitive; lower U.S. prices, particularly approaching European levels, shift semaglutide toward favorable value rather than a binary go/no-go determination. Patient ...

Novo Nordisk announced today that Health Canada has approved Ozempic® (semaglutide injection) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction ...